PTC Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 64.46 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.38B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children....